

Remarks

Claim 13, as originally written, referred back to base claim 2. However, this was an error, as evidenced by the fact that claim 2 does not recite a "vector." Instead, claim 13 should have referred to claim 3 and this has now been written into claim 13 to make it independent. The amendment does not add new matter to the application and its entry is respectfully requested.

Conclusion

In light of the amendments and remarks above, Applicant submits that the present application is now in condition for substantive review. If, in the opinion of the Examiner, a phone call may help to expedite the prosecution of this application, the Examiner is invited to call Applicant's undersigned attorney at (202) 419-7013.

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

By: Michael A. Sanzo
Michael A. Sanzo
Reg. No. 36,912
Attorney for Applicant

Date: October 31, 2002
1801 K St., NW, Suite 401L
Washington, DC 20006
(202)419-7013

Appendix

Version with Markings to Show Changes Made

Claim 13 was amended herein. This claim is shown below with underlined words indicating text that was added and bracketed words indicating text that was removed.

13. (Amended) A method for assaying a test compound for its ability to alter the expression of the human amyloid precursor protein, comprising:
- a) preparing [the] a vector [of claim 2;] for recombinantly expressing a peptide or protein in a eukaryotic cell, wherein said vector comprises:
 - i) a promoter which is active in said eukaryotic cell;
 - ii) a translation enhancer element consisting essentially of the nucleotide sequence of SEQ ID NO:1, wherein said element is 3' to said promoter;
 - iii) a DNA sequence encoding said peptide or protein, wherein said DNA sequence:
 - aa) lies 3' to said translation enhancer element;
 - bb) is operably linked to said promoter; and
 - cc) is non-homologous to said translation enhancer element;
 - b) measuring the expression of said gene in said vector in the absence of said test compound; and
 - c) comparing the expression determined in step b) with the expression of said gene in the presence of said test compound.